12:00 AM
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kalbitor ecallantide: Phase II started

Cubist began the double-blind, placebo-controlled, U.S. Phase II CONSERV-1 trial to evaluate 3 dosages of IV ecallantide in about 300 patients undergoing on-pump cardiothoracic surgery. The company has exclusive rights from Dyax to IV...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >